Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels
Alimentary Pharmacology & Therapeutics2019Vol. 49(10), pp. 1314–1322
Citations Over TimeTop 10% of 2019 papers
Amanda Nicoll, Stuart K. Roberts, Ricky Lim, Joanne Mitchell, Martin Weltman, Jacob George, Alan Wigg, Katherine Stuart, Paul Gow, Gerry MacQuillan, Edmund Tse, Miriam Levy, Siddharth Sood, Amany Zekry, Wendy Cheng, Jonathan Mitchell, Richard Skoien, William Sievert, Simone I. Strasser, Geoffrey W. McCaughan
Abstract
Mycophenolate remains an excellent treatment option for patients with AIH refractory to or intolerant of standard therapy with those most likely to benefit being older and/or having lower pre-treatment IgG levels.
Related Papers
- → Mycophenolate Mofetil for the Treatment of Autoimmune Hepatitis in Patients Refractory to Standard Therapy(2004)106 cited
- → Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis(2004)28 cited
- → Mycophenolate mofetil for patients with autoimmune hepatitis and overlap syndromes(2011)6 cited
- → Mycophenolate Mofetil is an effective alternative to Azathioprine in patients with severe autoimmune hepatitis(2003)
- → MYCOPHENOLATE MOFETIL IS AN EFFECTIVE ALTERNATIVE TO AZATHIOPRINE IN PATIENTS WITH SEVERE AUTOIMMUNE HEPATITIS(2003)